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Abstract
Healthcare delivery in the USA and abroad has changed dramatically over the last several decades. Along with the growth in diagnostic
and therapeutic interventions, the costs of healthcare have escalated out of proportion relative to other aspects of the economy. This
growth has fostered careful scrutiny of both the effectiveness and efﬁciency of healthcare delivery. Because of this emphasis on the
economics of healthcare, physicians require an understanding not only of the efﬁcacy and clinical utility of their interventions, but also
of the relative value in an economic sense of their efforts. In other words, physicians in the modern era must now appreciate the
concept of cost-effectiveness. Cost-effectiveness and cost–utility analyses are critical evaluative tools. Explicit data on comparative cost-
effectiveness are useful for allocating the increasingly stretched healthcare resources. This article provides a primer for understanding
the methods and applications of cost-effectiveness and cost–utility analyses.
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Introduction
Over the last several decades, healthcare expenditure in the
USA has escalated disproportionately with regard to the
general rate of inﬂation. Healthcare now accounts for a
staggering $2.1 trillion annually, representing 16% of the US
gross domestic product (http://www.oecd.org/dataoecd/48/4/
33727936.pdf (last accessed 27 November 2006)). This
means that for every $1 spent in the economy, 16 cents
goes towards healthcare. This relative amount of spending
exceeds the costs of healthcare in nearly every other nation,
including those that provide universal healthcare to their
citizens. These extensive healthcare expenditures are not
necessarily inappropriate. To determine whether costs are
‘appropriate’, one key issue is value. Any level of spending
may be acceptable, depending on the value provided by that
investment. Unfortunately, emerging facts about medical
errors and their costs [1], as well as our improved apprecia-
tion of the challenges of translating evidence into practice
[2], underscore the fact that healthcare delivery is fraught
with excess and waste.
Along these lines, and speciﬁcally for infectious diseases,
there has been a growing focus on healthcare-associated
infections (HAIs) as a marker of the quality of healthcare
delivered. Recent data suggest that in the USA there are
1.7 million episodes of HAI annually, resulting in 99 000
excess deaths, costing the healthcare system over $35 billion
[3,4].
These, and similar, revelations have prompted an
increased examination of and changes in the practice of med-
icine, with an eye towards questions of resource allocation
and efﬁciency. Moreover, there has been a general impres-
sion that a more vigorous move towards applying ‘evidence-
based medicine’ could be a means for improving both clinical
and economic outcomes [5]. In view of the sharply escalating
costs, however, this effort to translate the results of clinical
research into clinical practice must necessarily focus on efﬁ-
ciency. Conceptually, efﬁciency represents the notion of
attempting to obtain the most value and output for every
dollar spent. Hence, there is a growing interest in quantifying
the value of our healthcare interventions, which necessarily
relies on applying the methods of health economics. In this
ª2010 The Authors
Clinical Microbiology and Infection ª2010 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/j.1469-0691.2010.03331.x
article, we review some of the central methods of cost eval-
uation in healthcare, and provide examples of how they have
been used in the recent literature.
Methods for Evaluating Healthcare Costs
There are ﬁve major types of cost analysis: (i) cost minimiza-
tion; (ii) cost–beneﬁt; (iii) cost–consequence; (iv) cost-effec-
tiveness; and (v) cost-utility—the last two are encountered
most frequently in the medical literature. Brieﬂy, cost mini-
mization compares two interventions that produce identical
effects; such situations do not arise frequently. Cost–beneﬁt
analysis examines both costs and beneﬁts in terms of mone-
tary units, and cost–consequence is a type of analysis in
which costs and consequences are listed separately. Cost–
consequence analysis therefore allows the end-users to
choose the costs and the consequences most relevant to
their situations.
In medicine generally, and in infectious diseases speciﬁcally,
most research has taken the form of either cost-effectiveness
analyses (CEAs) or cost–utility analyses. Cost-effectiveness
refers to analyses that examine the ratio of the cost of a
particular intervention to a chosen unit of effectiveness. The
need for CEAs and cost–utility analyses (these terms are
sometimes used interchangeably) usually arises when the
value proposition of a new intervention is unclear. When a
new therapy, A, is cheaper and more effective than its com-
parator, B, it is said to ‘dominate’ the comparator—and in
such a case (albeit rare in medicine) the decision to adopt
therapy A is easy. Conversely, A is said to be dominated by
B if A is less effective and more costly than B. As with the
initial example, one’s preference is clear and one does not
require a formal evaluation. Ambiguity, on the other hand,
arises when either: (i) new therapy A is more effective and
more costly than comparator B; or (ii) new therapy A is less
effective and less costly than comparator B. Under these cir-
cumstances, it becomes important to articulate the resource
expenditure per unit of effectiveness. Put another way, one
needs a formal means for balancing the trade-offs between
the two interventions, so that one can make a rational deci-
sion that maximizes outcomes. Recognizing that CEAs had
become an important evaluative tool in medicine, a Panel on
Cost-effectiveness in Health and Medicine convened in the
mid-1990s to ‘develop consensus-based recommendations
for the conduct of cost-effectiveness analysis’ [6].
Perspective
‘Perspective’ refers to the point of view one takes when
conducting a CEA. It is critical to establish the perspective
utilized in any cost analysis. Perspective is crucial because it
determines which costs and outcomes are likely to matter
more than others. For example, in an intensive-care unit
(ICU) study, the cost of averting one case of ventilator-asso-
ciated pneumonia (VAP) is borne almost completely by the
hospital, and this is therefore an outcome that is important
from the hospital’s perspective. To the patient, however, the
development of VAP may affect morbidity but not necessarily
the direct costs that the patient must pay. Other perspec-
tives may represent those of payers, pharmacies, the ICU (as
a cost centre) and others. Clearly, shifting of certain costs
may be attractive to those whose costs are diminished, and
far less so to those who must bear the additional cost bur-
den. As one can see, the costs and beneﬁts of any interven-
tion may not be borne equally, and therefore if one does
not look at these variables from a broad enough perspective,
one might develop a skewed assessment of an intervention.
Taking the broadest approach to perspective helps avoid a
potential bias in CEA. This dilemma led to the principle in
CEA that one should adopt a societal perspective. From a
societal vantage, one can incorporate all costs, no matter on
whom they individually fall. When reading CEAs, readers can
quickly ascertain whether the authors have utilized a societal
perspective. Generally, such articles will describe results in
terms of a reference case. The reference case describes the
baseline scenario that the analyst is exploring, and serves as
the frame of reference for other comparisons. The reference
case incorporates quality-adjusted life-years (QALYs) in the
denominator of the cost-effectiveness ratio. This, by deﬁni-
tion, represents the societal perspective, and is therefore
most important for public health and overall resource
allocation.
Recognizing the need to be explicit regarding the per-
spective taken, the Panel on Cost-effectiveness in Health
and Medicine recommends that every CEA include a refer-
ence case [6]. The calculation of the reference case
requires a longer-term evaluation of both costs (lifetime
healthcare costs) and effectiveness outcomes. Included in
the denominator are not only expected years of survival,
factoring in the speciﬁc life-expectancy for survivors of the
disease in question, but also the quality of life of those
years. This is necessary because some interventions or
therapies may restore a person to perfect health, whereas
others, while extending life, still leave the person in a debili-
tated state. Reliance on the concept of QALYs is necessar-
ily utilitarian from a philosophical perspective, and is fraught
with ethical issues. This fact demonstrates why CEA cannot
be applied either as a trump in policy analysis or in the
absence of a framework for ensuring that important societal
values are not vitiated.
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The usual denominator in cost–utility studies is the QALY,
and cost per QALY serves as the reference case. Addition-
ally, reference cases are useful because they provide a base-
line scenario against which to compare alternative resource
allocation decisions—it is valid to compare the costs per
QALY in reference cases across unrelated conditions and
interventions. Whereas data regarding long-term outcomes
for chronic conditions may be broadly available for research-
ers to apply in CEA, those for acute and short-lived
episodes, such as those that arise with infectious disease,
may not exist. To circumvent this challenge, investigators
regularly adopt the technique of decision modelling.
Examples of modelling
A recent study by Angus et al. [7] of drotrecogin alfa (acti-
vated) in severe sepsis represents a CEA in the setting of an
infection that incorporates both real-time data from a clinical
trial and modelling. In this study, the investigators examined
the incremental healthcare costs associated with one death
averted at 28 days as a result of treatment with drotrecogin
alfa (activated). To determine overall costs, the authors
needed not only to establish the costs of drotrecogin alfa
(activated), but also to take into account the fact that survi-
vors require continued care and thus consume further
healthcare resources. In other words, treatment with drotr-
ecogin alfa (activated) has many implications beyond just the
costs related to purchasing the drug. Angus et al. estimated
that drotrecogin alfa (activated) cost society $160 000 per
one life saved. In determining the reference case, which
required estimating the life-expectancy of sepsis survivors
and the quality of their additional years of life, the authors
found that drotrecogin alfa (activated) cost $48 000 per
QALY [7]. This ratio improved to $27 000 per QALY when
the estimated risk of short-term death increased, and wors-
ened dramatically, exceeding $100 000 per QALY, if the sur-
vivors had an overall estimated life-expectancy of <5 years.
For this study, the cost per death avoided was calculated
on the basis of the actual data collected in the trial, but the
cost–utility ratio was based on a modelling exercise. In the
model, assumptions about long-term outcomes, based on
previous work in septic populations, were put into a mathe-
matical formula, which, in turn, generated the outcome esti-
mates of interest. This is a preferred approach to building a
reference case, as practical considerations, such as the
urgency of the need for cost-effectiveness information and
the enormous resources required, preclude real-time collec-
tion of the actual long-term outcomes.
CEAs in infectious disease have also dealt with issues that
inform public policy decisions when society is faced with a
novel health threat. For example, Khazeni et al. [8] examined
the costs and effectiveness of a public health interven-
tion—vaccination against pandemic inﬂuenza (H1N1). Utiliz-
ing a compartmental epidemic model along with a Markov
analysis, and inputting well-documented assumptions, the
authors concluded that vaccinating approximately 40% of the
population of a hypothetical US city (population 8.3 million)
in October or November 2009 would not only be life-saving,
but also cost-saving. In the reference case, for instance, vac-
cinating 40% of the at-risk population in October would add
nearly 70 000 QALYs and save $469 million [8].
Another example of using modelling to arrive at a reason-
able epidemic response is a recent study by Dan et al. [9]. In
their model, the investigators attempted to deﬁne the most
balanced approach to H1N1 hospital outbreak prevention in
Singapore. They began their analysis by taking into account
their local experience with the SARS epidemic. The authors
examined the cost-effectiveness of a ﬁve-level response,
considering both viral and outbreak characteristics. The ﬁve
levels of response ranged from Green, representing the situ-
ation when no active virus is circulating, to Red, when a pan-
demic is underway and viral import into Singapore is
inevitable. In this simulation exercise, based on assumptions
about the infectivity and case-fatality rate of H1N1, with the
Green level of response (e.g. corresponding to personal pro-
tective equipment for healthcare workers in direct contact
with infected patients) all but a single death in the population
would be averted in the model. They estimated that this
would occur at a cost of $23 000. Although, under their
proposed Yellow level of response, all H1N1 deaths would
be averted, preventing each additional death would cost
$828 000. Escalating the alert to Red level would reduce
further infections, but would not have an additional impact
on mortality. In this scenario, the overall costs would reach
an untenable $2.5 million to avert one H1N1-related death.
Clearly, the model by Dan et al. illustrates the usefulness of
deﬁning different scenarios explicitly and transparently in
order to model the implications of alternative options and
thus to allow one to institute the most sensible healthcare
policy [9].
Incremental cost-effectiveness ratio
Comparative effectiveness research (CER) represents a use-
ful application of CEAs and cost–utility analyses. The purpose
of CER is to compare explicitly the effectiveness of two
interventions used for the same condition. Although, as a
point of policy in the USA, the place of cost analyses remains
vague, some have advocated that cost-effectiveness is an
essential component of CER [10]. The single value represent-
ing comparative cost-effectiveness is the incremental cost-
effectiveness ratio (ICER).
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Shorr et al., for example, explicitly examined the cost-
effectiveness of linezolid as compared with vancomycin for
the treatment of methicillin-resistant Staphylococcus aureus
VAP [11]. Here, the ICER was calculated as the ratio of the
differences in costs to the differences in effectiveness mea-
sures of the two therapies being compared. By deﬁnition,
the lower the ICER, the better the cost-effectiveness proﬁle.
Methodologically, Shorr’s study relied fully on a model-build-
ing approach, examining multiple outcomes of interest. In the
base-case analyses, the estimates were approximately
$67 000, $22 000 and $30 000 for incremental costs per
survivor, per life-year saved, and per QALY, respectively
[11].
Sensitivity analyses
Because model inputs are based on assumptions, albeit opti-
mally derived from the literature, they necessarily include a
degree of uncertainty. Sensitivity analyses are designed to
estimate how this uncertainty in the assumptions may impact
on the precision of the outcome estimates [6]. These sensi-
tivity analyses usually include univariate (where one input is
varied at a time), two-way (where two of the inputs with
the strongest effect on the outcome variability are varied at
the same time) and multivariate (where all of the inputs are
varied at the same time across their plausibility ranges) analy-
ses. Readers should look sceptically at CEAs that do not
report sensitivity analyses. For example, in a recent cost-
effectiveness simulation of the silver-coated endotracheal
tube as a VAP-preventive measure, the authors found the
intervention to be overall cost-saving in the base case [12].
Because univariate analyses indicated that VAP costs and the
risk reduction resulting from use of the novel endotracheal
tube accounted for most of the uncertainty in the model, a
two-way sensitivity analysis was performed in which these
parameters were altered simultaneously across their respec-
tive ranges of uncertainty. The extent of uncertainty
employed in sensitivity analyses is most appropriate if
derived from actual clinical data, and should represent the
95% CIs around various point estimates. In the endotracheal
tube study, the sensitivity analysis revealed outcome esti-
mates ranging from savings of $34 000 to an expenditure of
$205 to prevent one case of VAP [12].
Another useful sensitivity analysis is a worst-case scenario
analysis, where all inputs are biased against one of the com-
parators (usually the novel intervention). In a study of the
cost-effectiveness of micafungin as compared with ﬂucona-
zole for empirical treatment of cadidaemia in the ICU, the
calculated cost per QALY was $35 000. In the worst-case
scenario, the cost–utility ratio gave a cost of $72 000 to save
one additional QALY [13]. A further threshold analysis was
performed in the same study [13]. Because cost estimates
can be exquisitely sensitive to the population studied, the
authors sought to evaluate the threshold impact of azole
resistance that would push the cost–utility ratio into the tra-
ditionally non-cost-effective range of >$100 000 per QALY.
Gradual adjustment of this input suggested that when the
prevalence of azole resistance reached 1.5%, micafungin was
no longer cost-effective relative to ﬂuconazole [13].
Inﬂation adjustments and discounting
Two other recommendations by the Panel on Cost-effective-
ness in Health and Medicine, to adjust costs for inﬂation and
to discount both future costs and effectiveness estimates,
can be used as markers of the study’s quality [6]. Inﬂation
adjustment is necessary for several reasons. Because medical
cost inﬂation shifts rapidly, costs need to be adjusted to the
current time. In other words, a dollar spent today is not of
the same true value as a dollar spent in the future. More
importantly, because cost parameters may be derived from
varied sources that make calculations in different years, inﬂa-
tion adjustment to the same year is applied for the sake of
uniformity and to simply be able to ‘compare apples with
apples’.
Furthermore, humans value money and other goods more
in the current time than in the future. This also explains why
one needs to discount future costs and outcomes. There-
fore, any analysis quantifying future costs (e.g. lifetime health-
care costs) and outcomes (e.g. QALYs) needs adjustment for
this factor. More importantly, these adjustments must be
made in both the numerator and the denominator of any
cost-effectiveness ratio. The recommended annual base
discount rate is 3%, with the range around it being between
0% and 7% [6].
Types of cost
There are several terms that readers should understand as
they relate to types of cost. An important distinction exists
between charges and costs. Charges reﬂect the desired
reimbursement rates for a hospital or a healthcare provider.
Included in this value may be not only the true expenditures
for the care along with some measure of reasonable proﬁt,
but also proﬁt-maximizing strategies [14]. Because of this
and the highly variable nature of charges, costs are the pre-
ferred numerator for CEAs. Costs are meant to represent
the actual consumption of resources, whereas charges simply
represent an accounting tool.
Costs can be derived from charges on the basis of the
published hospital-speciﬁc cost/charge ratios from Medicare.
Costs can also be direct, indirect or intangible. Similarly, they
can be either ﬁxed or variable. Direct costs are those of
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labour and goods utilized in the delivery of the intervention.
Indirect costs, on the other hand, are those attributable to
lost productivity resulting from illness. Intangible costs incor-
porate the pain and suffering resulting form the disease and/
or intervention. Fixed costs are those that remain the same
regardless of the amount of production output. In a hospital
setting, these include costs associated with running the physi-
cal plant and equipment. Variable costs are those that do
tend to change in the short term with the changes in
production output, such as costs of having to increase the
number of nursing staff because of a temporary surge in ICU
volume.
There is controversy regarding whether CEA should
address ﬁxed, variable or total (the sum of ﬁxed and variable)
costs. This dilemma is particularly acute when costing out a
disease or an intervention in the ICU. Although most studies
take the total cost approach, it appears that variable costs
may be more subject to being inﬂuenced by interventions
[15]. In other words, one cannot save ‘ﬁxed’ costs—they will
accrue no matter what transpires. At the same time, how-
ever, ﬁxed costs are also subject to external pressures, albeit
over longer periods of time. Therefore, they need to be
taken into account. Analysing ﬁxed vs. variable costs can
result in vastly different estimates of the cost of an illness.
For example, according to a study by Dasta et al. [16], the
total cost for the ﬁrst day of ICU care in the USA for a
patient with respiratory failure approaches $8000. However,
this cost diminishes for subsequent days to $3600–3900
(2002 $US). Conversely, Kahn et al. [15] calculated that the
direct variable costs of the last ICU day in a cohort of similar
patients who survived beyond ICU day 3 was $400, with the
ﬁrst ward day cost totalling only $280. On the basis of this
accounting, a hypothetical intervention that reduces the ICU
length of stay (LOS) by 1 day saves the hospital only $120.
Alternatively, if the data from Dasta et al. were utilized in a
CEA, entirely different conclusions might be drawn.
Are bundled interventions cost-effective?
Translating evidence into practice generally relies on adopt-
ing a conglomeration of interventions, rather than a single
treatment. Hence, it is important to ask whether some of
the currently recommended bundled interventions for quality
improvement are cost-effective. Two such potentially costly
bundled strategies include early goal-directed therapy
(EGDT) for sepsis and a shift to a 24-h intensivist model for
ICU stafﬁng. Huang et al. examined the cost-effectiveness of
EGDT from both the hospital and societal perspectives. They
concluded that EGDT had a nearly 100% probability of being
cost-effective at a value of <$20 000 per QALY [17]. On the
other hand, the cost-effectiveness of different models of ICU
coverage remains poorly understood. For example, a 24-h in-
tensivist model for ICU coverage is thought to be cost-saving
from the perspective of the hospital—the intensivist
approach can improve outcomes, enhance patient ﬂow, and
focus on prevention [18]. However, this policy’s cost-effec-
tiveness from the societal perspective has not been deﬁni-
tively shown. The savings associated with implementation of
this model derive largely from an anticipated reduction in
the ICU and hospital LOS. On the one hand, it seems quite
reasonable to believe that a 24-h intensivist model will not
alter post-ICU survivorship, either in the intermediate or in
the long term. As a result, any savings from a near-term
shortening of LOS may be offset by an increase in post-
hospitalization mortality or a reduced duration of survival
[19]. Again, this conundrum illustrates the need to be
explicit about perspective and sensitivity analyses when
conducting CEA.
Strikingly, some of the bundled interventions for HAI
prevention, which many strictly advocate, have not been
evaluated either for their effectiveness or for their
cost-effectiveness. One such example includes the Institute
for Healthcare Improvement’s ventilator bundle [20]. In a
recent systematic review of studies evaluating bundled
interventions for prevention of VAP, the authors found weak
evidence for the effectiveness of this approache. More
importantly, they found no rigorous evaluations of the cost-
effectiveness of ventilator bundles for avoiding VAP [21]. As
more and more bundled strategies are promoted as quality
measures and criteria for reimbursement, a critical approach
to their cost-effectiveness becomes essential. Although, for
example, preventing VAP is important, the resources
available to accomplish this are limited, and reﬂexive
adoption of some strategies for this might result in the
diversion of resources from more cost-effective approaches.
Conclusions
The rapid growth in healthcare expenditure has engendered
careful scrutiny of the practice of medicine with regard not
only to effectiveness, but also to efﬁciency. This shift necessi-
tates that physicians understand the effectiveness of their
interventions and the cost at which this effectiveness is
obtained. CEAs and cost–utility analyses have become critical
evaluative tools in medicine. Explicit articulation of compara-
tive cost-effectiveness facilitates the determination of how to
allocate limited resources. As physicians encounter CEA in
the literature, they must evaluate such studies as they would
any clinical study—with caution, scepticism, and attention to
the methods utilized.
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